Minakem-flap

Minakem-flap

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Pipeline Developments & Deals by Insignis Therapeutics

All Data

Filters

refresh

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

refresh

Companies By Therapeutic Area

Development Status

Insignis Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

PBP 12th World Meeting

Participation Not Confirmed

Update your events

Insignis Therapeutics and HLK Pharmacin Receive FDA IND Clearance to Initiate a Phase 1 Trial With IN-001 for Oral Anaphylaxis Treatment

Contact the Supplier

Lead Product(s): IN-001

Therapeutic Area: Immunology Product Name: IN-001

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: HLK Pharmacin

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 29, 2020

Details:

The Phase 1 single dose study in healthy volunteers will compare IN-001 orally dissolving tablet (epinephrine prodrug) vs the current standard of care, EPIPEN (epinephrine injection).